Ultrasound guided management of renal failure in Cirrhosis

Phase 2/3

Not yet recruiting

Conditions: Fibrosis and cirrhosis of liver,

Registration Number: CTRI/2025/06/088973

Lead Sponsor: INHS Kalyani

Brief Summary: Acute kidney injury (AKI) in patients with cirrhosisis commonly multifactorial. Both diagnosis and management in such cases can bechallenging. In many patients, a definitive diagnosis cannot be establishedthrough patient history, physical examination, or standard laboratory tests,especially when AKI has a hemodynamic origin, such as hepatorenal syndrome.Current guidelines offer broad recommendations, including stopping diureticsand administering albumin for 48 hours to expand plasma volume. However, theseapproaches can sometimes be ineffective or even harmful, potentially leading tocomplications like fluid overload and acute cardiogenic pulmonary edema. Giventhese limitations, newer diagnostic tools like hemodynamic point-of-careultrasound (PoCUS) provide a more precise assessment of a patient’s volumestatus. This technology enables a rapid, noninvasive, and personalized approachto guiding medical treatment.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 120

Inclusion Criteria

All patients of chronic liver disease (diagnosed by clinical, biochemical, imaging criteria) presenting with Acute kidney injury per KDIGO criteria.

Exclusion Criteria

1.Established chronic kidney disease (as per KDIGO criteria) stage 3-5 2.Patients on dialysis 3.Patients on mechanical ventilator 4.Conditions in whom technically POCUS could not be done 5.Non Cooperative patient.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.Recovery of AKI (?20 % decrease ( partial recovery) in serum creatinine or return to baseline) by day 7	7 days
2.Duration in days to attain renal recovery ( return of creatinine level to partial or complete recovery)	7 days

Secondary Outcome Measures

Name	Time	Method
1.30-day mortality	2.Therapy adjustments (e.g., fluids, use of diuretic, Inj albumin, day of hospitalization terlipressin use) compared between groups

Trial Locations

Locations (1): Dept of Nephrology and Dialysis, INHS Kalyani
🇮🇳
Visakhapatnam, ANDHRA PRADESH, India
Dept of Nephrology and Dialysis, INHS Kalyani
🇮🇳Visakhapatnam, ANDHRA PRADESH, India
Dr Vineet Behera
Principal investigator
9673470724
vineetbeheraaiims@gmail.com